Minnesota Glomerular Disease Program

Minnesota Glomerular

Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller

Mission

To provide patients with glomerular disease with expert, individualized care and access to clinical trials.

Covered Diseases

  • Any glomerular disease, including (but not limited to):
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Membranous nephropathy
    • Minimal change disease 
    • IgA nephropathy
    • Immune complex mediated diseases
    • C3 Glomerulopathy
    • Fibrillary Glomerular Disease
    • Cryoglobulinemia
    • Anti-Glomerular Basement Membrane (anti-GBM) Disease
    • Alport Syndrome
    • Thin basement membrane disease
    • Vasculitis
    • Lupus Nephritis
  • For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage

Goals

  • Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with glomerular disease.

Our Team

Physicians

Clinical & Translational Research Team

Ongoing Clinical Trials

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Phase 2a Trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

IGA NEPHROPATHY

Phase 3 Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Principal Investigator
Patrick H. Nachman, MD

Co-Investigators
Surabhi Thakar, MD

Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL


Phase 3 Trial

Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy

Principal Investigator
Sahar Koubar, MBBS
Co-Investigators
Nattawat Klomjit, MD
Patrick H. Nachman, MD

Study Coordinators
Joy Bolea, RN, MS
jbolea@umn.edu

CLINICAL TRIAL

MEMBRANOUS NEPHROPATHY

Phase 2 Trial

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

Principal Investigator

Patrick H. Nachman, MD

Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

Joy Bolea, RN, MS
jbolea@umn.edu

CLINICAL TRIAL